CRISPR DNA Editing Can Cause Hundreds of Off-Target Mutations
By Dave Roos,
Seeker [cites Marcy Darnovsky]
| 06. 06. 2017
A new study offers a cautionary tale for using the widely hyped gene-editing tool CRISPR on people.
The gene-editing technology known as CRISPR has only been around for five years, but it’s already generated enough hype and controversy to last a lifetime. Compared to other gene-editing techniques, CRISPR is so fast, cheap, and precise that any scientist with a basic understanding of genetics can experiment with DNA — plant, animal, or human — by cutting out and replacing specific genes.
Some say that the ease and effectiveness of CRISPR will usher in a golden age of genetic modification resulting in new cures for inherited diseases like Huntington’s and muscular dystrophy and new gene therapies for eradicating cancer and HIV. Others see CRISPR as a Pandora’s box leading to a dystopian future of designer babies and expensive life-extending therapies that will further divide the world into genetic haves and have nots.
Now a new study complicates the CRISPR controversy by shining a light on CRISPR’s Achilles' heel — off-target mutations. CRISPR works by targeting short sequences of DNA base pairs in...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...